Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share

9 Months Ended

Sep. 30, 2019

Loss per share

Loss per share

Note 6 — Loss per share

The numerator for the basic and diluted (loss) income per share is as follows (in thousands):


	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
Net (loss) income attributable to ordinary shareholders	$	(39,302)	$	5,242	$	(107,801)	$	(59,341)
Numerator for basic (loss) income per share		(39,302)		5,242		(107,801)		(59,341)
Numerator for diluted (loss) income per share		(39,302)		5,242		(107,801)		(59,341)

The denominator for the basic and diluted (loss) income per share is as follows:


	Three months ended		Nine months ended
	September 30,		September 30,
	2019	2018	2019	2018
Denominator for basic (loss) income per share - Weighted average shares outstanding	630,866,800	582,004,954	629,403,293	573,796,275
Effect of dilutive securities:
Employee stock options	—	39,759,247	—	—
Denominator for diluted (loss) income per share	630,866,800	621,764,201	629,403,293	573,796,275

The dilutive effect of 90,072,300 stock options outstanding as of September 30, 2019 have been excluded from the diluted loss per share calculation for the three and nine months ended September 30, 2019, because they would have an antidilutive effect on the loss per share for the period.

The dilutive effect of 2,791,651 and 88,869,497 stock options have been excluded from the diluted earnings (loss) per share calculation for the three and nine months ended September 30, 2018, respectively, because they would have an antidilutive effect on the earnings (loss) per share for the period.